# MTCH2

## Overview
MTCH2, or mitochondrial carrier homolog 2, is a gene that encodes the mitochondrial carrier protein 2, a transmembrane protein localized to the outer mitochondrial membrane. Unlike typical mitochondrial carriers, MTCH2 does not form a pore for transporting charged species but instead functions as a protein insertase, facilitating the integration of specific proteins into the mitochondrial outer membrane (Guna2022MTCH2; Robinson2012Mitochondrial). The protein is characterized by its unique structural features, including six transmembrane α-helices and a prominent groove essential for its role in apoptosis regulation and mitochondrial dynamics (Guna2022MTCH2; Gross2005Mitochondrial). MTCH2 is involved in various cellular processes, including mitochondrial fusion, apoptosis, and the regulation of mitochondrial morphology and metabolism, impacting cellular differentiation and cognitive functions (Ruggiero2017Loss; Bahat2018MTCH2mediated). Its clinical significance is underscored by its association with metabolic disorders, cancer progression, and neurodegenerative diseases, highlighting its potential as a therapeutic target (BuzagloAzriel2016Loss; Khan2023Identification; Ruggiero2017Loss).

## Structure
MTCH2 is a mitochondrial carrier protein with a sequence approximately 300 amino acids long, featuring a mitochondrial carrier domain (MCD) composed of three tandem repeats, each containing two hydrophobic helices separated by a hydrophilic region (Gross2005Mitochondrial; Robinson2012Mitochondrial). The protein is characterized by six transmembrane α-helices, with both the N- and C-termini facing the intermembrane space (IMS) (Gross2005Mitochondrial). Unlike typical mitochondrial carriers, MTCH2 is localized to the outer mitochondrial membrane and does not form a pore for transporting charged species (Guna2022MTCH2; Robinson2012Mitochondrial).

MTCH2 has unique structural features, such as a shorter TMH1 and a highly diverged TMH6 with more hydrophilic residues, which may contribute to its modified function compared to other mitochondrial carriers (Robinson2012Mitochondrial). The protein also contains a 'Gly-Asp' pair at its substrate binding site, indicating potential differences in substrate recognition (Robinson2012Mitochondrial). MTCH2's structure includes a prominent groove lined with charged and polar residues, essential for its role as a protein insertase (Guna2022MTCH2). The protein's interaction with tBID, a proapoptotic protein, suggests a role in apoptosis regulation (Katz2012Molecular).

## Function
MTCH2 (mitochondrial carrier homolog 2) is a protein that plays a crucial role in the insertion of α-helical proteins into the mitochondrial outer membrane. It functions as a mitochondrial outer membrane protein insertase, essential for the proper integration of tail-anchored (TA), signal-anchored, and multipass proteins, but not for β-barrel proteins (Guna2022MTCH2). MTCH2 acts as a gatekeeper, preventing the mislocalization of mitochondrial TAs to the endoplasmic reticulum, thereby influencing cellular distribution and sensitivity to apoptotic stimuli (Guna2022MTCH2).

MTCH2 is also involved in mitochondrial dynamics, particularly in mitochondrial fusion, which is vital for cellular differentiation processes. It is essential for the transition from naïve to primed pluripotency in embryonic stem cells, where it regulates mitochondrial morphology and metabolism (Bahat2018MTCH2mediated). In neurons, MTCH2 is critical for mitochondrial motility and calcium handling, impacting cognitive functions such as learning and memory (Ruggiero2017Loss).

MTCH2's role extends to apoptosis, where it acts as a mitochondrial hub for pro-apoptotic BCL-2 family members, facilitating interactions that are crucial for programmed cell death (Robinson2012Mitochondrial). Its unique localization to the outer mitochondrial membrane and structural features suggest specialized functions beyond traditional transport roles (Robinson2012Mitochondrial).

## Clinical Significance
Mutations and alterations in the MTCH2 gene have been implicated in various diseases and conditions. In the context of metabolic disorders, MTCH2 is a critical regulator of mitochondrial mass and metabolism. Its deficiency in muscle tissue has been shown to increase mitochondrial mass and metabolism, leading to elevated energy expenditure and protection against diet-induced obesity, suggesting a potential role in metabolic diseases such as diabetes and obesity (BuzagloAzriel2016Loss).

In cancer, MTCH2 expression is associated with tumor progression and poor prognosis. In glioblastoma, a mutation in MTCH2 was identified as potentially deleterious, contributing to rapid tumor progression and chemoresistance (Khan2023Identification). In glioma, high MTCH2 expression correlates with poor patient survival, and its knockdown increases sensitivity to the chemotherapy drug temozolomide (Yuan2021Inhibition). MTCH2 also plays a role in ovarian cancer progression by promoting mitochondrial dysfunction and energy metabolism alterations (Sun2024MTCH2).

In neurodegenerative diseases, MTCH2 deregulation is linked to Alzheimer's disease, where its deficiency in the forebrain impairs cognitive functions such as spatial memory and long-term potentiation, potentially contributing to disease pathogenesis (Ruggiero2017Loss).

## Interactions
MTCH2 (mitochondrial carrier homolog 2) is known for its interactions with the proapoptotic truncated BID (tBID) protein, which is crucial in the mitochondrial apoptotic pathway. MTCH2 recruits tBID to the mitochondria in response to apoptotic signals, facilitating the activation of Bax/Bak and subsequent apoptosis (Katz2012Molecular). The interaction between MTCH2 and tBID involves specific binding sites: tBID residues 59-73 bind to MTCH2 residues 140-161, and tBID residues 111-125 bind to MTCH2 residues 240-290 (Katz2012Molecular). These interactions are partly electrostatic and have been shown to induce cell death in osteosarcoma cells, suggesting potential therapeutic applications (Katz2012Molecular).

MTCH2 is also part of a larger mitochondrial complex that includes BAX, indicating its role in tBID-induced activation of BAX (Grinberg2005Mitochondrial). The formation of a 45-kDa complex composed of tBID and MTCH2 is observed in cells treated with tumor necrosis factor alpha (TNF-α), highlighting its involvement in apoptotic signaling pathways (Grinberg2005Mitochondrial). Despite its association with apoptotic proteins, MTCH2 itself does not appear to be pro-apoptotic, as its overexpression does not affect cell viability (Grinberg2005Mitochondrial).


## References


[1. (Katz2012Molecular) Chen Katz, Yehudit Zaltsman-Amir, Yana Mostizky, Neta Kollet, Atan Gross, and Assaf Friedler. Molecular basis of the interaction between proapoptotic truncated bid (tbid) protein and mitochondrial carrier homologue 2 (mtch2) protein. Journal of Biological Chemistry, 287(18):15016–15023, April 2012. URL: http://dx.doi.org/10.1074/jbc.M111.328377, doi:10.1074/jbc.m111.328377. This article has 54 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M111.328377)

[2. (Ruggiero2017Loss) Antonella Ruggiero, Etay Aloni, Eduard Korkotian, Yehudit Zaltsman, Efrat Oni-Biton, Yael Kuperman, Michael Tsoory, Liat Shachnai, Smadar Levin-Zaidman, Ori Brenner, Menahem Segal, and Atan Gross. Loss of forebrain mtch2 decreases mitochondria motility and calcium handling and impairs hippocampal-dependent cognitive functions. Scientific Reports, March 2017. URL: http://dx.doi.org/10.1038/srep44401, doi:10.1038/srep44401. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep44401)

[3. (Grinberg2005Mitochondrial) Michal Grinberg, Michal Schwarz, Yehudit Zaltsman, Tzipi Eini, Hagit Niv, Shmuel Pietrokovski, and Atan Gross. Mitochondrial carrier homolog 2 is a target of tbid in cells signaled to die by tumor necrosis factor alpha. Molecular and Cellular Biology, 25(11):4579–4590, June 2005. URL: http://dx.doi.org/10.1128/mcb.25.11.4579-4590.2005, doi:10.1128/mcb.25.11.4579-4590.2005. This article has 83 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.25.11.4579-4590.2005)

[4. (Bahat2018MTCH2mediated) Amir Bahat, Andres Goldman, Yehudit Zaltsman, Dilshad H. Khan, Coral Halperin, Emmanuel Amzallag, Vladislav Krupalnik, Michael Mullokandov, Alon Silberman, Ayelet Erez, Aaron D. Schimmer, Jacob H. Hanna, and Atan Gross. Mtch2-mediated mitochondrial fusion drives exit from naïve pluripotency in embryonic stem cells. Nature Communications, December 2018. URL: http://dx.doi.org/10.1038/s41467-018-07519-w, doi:10.1038/s41467-018-07519-w. This article has 57 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-018-07519-w)

[5. (Guna2022MTCH2) Alina Guna, Taylor A. Stevens, Alison J. Inglis, Joseph M. Replogle, Theodore K. Esantsi, Gayathri Muthukumar, Kelly C. L. Shaffer, Maxine L. Wang, Angela N. Pogson, Jeff J. Jones, Brett Lomenick, Tsui-Fen Chou, Jonathan S. Weissman, and Rebecca M. Voorhees. Mtch2 is a mitochondrial outer membrane protein insertase. Science, 378(6617):317–322, October 2022. URL: http://dx.doi.org/10.1126/science.add1856, doi:10.1126/science.add1856. This article has 76 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.add1856)

[6. (Robinson2012Mitochondrial) Alan J. Robinson, Edmund R.S. Kunji, and Atan Gross. Mitochondrial carrier homolog 2 (mtch2): the recruitment and evolution of a mitochondrial carrier protein to a critical player in apoptosis. Experimental Cell Research, 318(11):1316–1323, July 2012. URL: http://dx.doi.org/10.1016/j.yexcr.2012.01.026, doi:10.1016/j.yexcr.2012.01.026. This article has 35 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.yexcr.2012.01.026)

[7. (BuzagloAzriel2016Loss) Liat Buzaglo-Azriel, Yael Kuperman, Michael Tsoory, Yehudit Zaltsman, Liat Shachnai, Smadar Levin Zaidman, Elad Bassat, Inbal Michailovici, Alona Sarver, Eldad Tzahor, Michal Haran, Cecile Vernochet, and Atan Gross. Loss of muscle mtch2 increases whole-body energy utilization and protects from diet-induced obesity. Cell Reports, 14(7):1602–1610, February 2016. URL: http://dx.doi.org/10.1016/j.celrep.2016.01.046, doi:10.1016/j.celrep.2016.01.046. This article has 36 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.celrep.2016.01.046)

[8. (Yuan2021Inhibition) Qiuyun Yuan, Wanchun Yang, Shuxin Zhang, Tengfei Li, Mingrong Zuo, Xingwang Zhou, Junhong Li, Mao Li, Xiaoqiang Xia, Mina Chen, and Yanhui Liu. Inhibition of mitochondrial carrier homolog 2 (mtch2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma. Molecular Medicine, January 2021. URL: http://dx.doi.org/10.1186/s10020-020-00261-4, doi:10.1186/s10020-020-00261-4. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s10020-020-00261-4)

[9. (Sun2024MTCH2) Guangyu Sun, Yanmin Song, Congxian Li, Bo Sun, Chengcheng Li, Jinbao Sun, Ping Xiao, and Zhengmao Zhang. Mtch2 promotes the malignant progression of ovarian cancer through the upregulation of aimp2 expression levels, mitochondrial dysfunction and by mediating energy metabolism. Oncology Letters, August 2024. URL: http://dx.doi.org/10.3892/ol.2024.14625, doi:10.3892/ol.2024.14625. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ol.2024.14625)

[10. (Gross2005Mitochondrial) Atan Gross. Mitochondrial carrier homolog 2: a clue to cracking the bcl-2 family riddle? Journal of Bioenergetics and Biomembranes, 37(3):113–119, June 2005. URL: http://dx.doi.org/10.1007/s10863-005-6222-3, doi:10.1007/s10863-005-6222-3. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10863-005-6222-3)

[11. (Khan2023Identification) Imran Khan, Esra Büşra Işık, Sadaf Mahfooz, Asif M. Khan, and Mustafa Aziz Hatiboglu. Identification of genetic alterations in rapid progressive glioblastoma by use of whole exome sequencing. Diagnostics, 13(6):1017, March 2023. URL: http://dx.doi.org/10.3390/diagnostics13061017, doi:10.3390/diagnostics13061017. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/diagnostics13061017)